ImmunoGen, Inc. (IMGN) Shares Gap Up to $6.69

ImmunoGen, Inc. (NASDAQ:IMGN)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $6.55, but opened at $6.69. ImmunoGen shares last traded at $6.99, with a volume of 4,299,630 shares changing hands.

IMGN has been the topic of several analyst reports. Leerink Swann reissued an “outperform” rating and issued a $11.00 target price (up previously from $8.00) on shares of ImmunoGen in a research note on Monday, June 19th. ValuEngine raised ImmunoGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. William Blair reissued an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. Royal Bank Of Canada set a $5.00 target price on ImmunoGen and gave the company a “hold” rating in a research note on Monday, June 26th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $6.00 target price on shares of ImmunoGen in a research note on Wednesday, June 28th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. ImmunoGen has an average rating of “Hold” and an average price target of $8.05.

The stock has a 50 day moving average of $7.12 and a 200 day moving average of $5.61. The firm’s market capitalization is $626.28 million.

ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $39.02 million during the quarter, compared to analyst estimates of $30.59 million. The firm’s revenue for the quarter was up 426.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.53) earnings per share. Analysts predict that ImmunoGen, Inc. will post ($0.74) EPS for the current fiscal year.

In other news, VP Craig Barrows sold 14,600 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total value of $101,470.00. Following the transaction, the vice president now directly owns 51,100 shares of the company’s stock, valued at approximately $355,145. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.51% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of IMGN. Teachers Advisors LLC increased its position in ImmunoGen by 10.6% in the 4th quarter. Teachers Advisors LLC now owns 209,859 shares of the biotechnology company’s stock valued at $428,000 after buying an additional 20,171 shares in the last quarter. Bank of New York Mellon Corp increased its position in ImmunoGen by 15.4% in the 1st quarter. Bank of New York Mellon Corp now owns 438,917 shares of the biotechnology company’s stock valued at $1,698,000 after buying an additional 58,516 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in ImmunoGen by 148.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 68,097 shares of the biotechnology company’s stock valued at $264,000 after buying an additional 40,700 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in ImmunoGen in the 1st quarter valued at about $1,528,000. Finally, Parametric Portfolio Associates LLC increased its position in ImmunoGen by 7.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 2,753 shares in the last quarter. 65.66% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/10/10/immunogen-inc-imgn-shares-gap-up-to-6-69.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

What are top analysts saying about ImmunoGen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ImmunoGen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit